OrganoTherapeutics and molmir Announce Strategic Collaboration to Accelerate Neurodegenerative Disease Research

OrganoTherapeutics is proud to announce a new strategic collaboration with molmir, a Japanese deep-tech startup pioneering molecular dynamics detection technologies.

This collaboration aims to combine OrganoTherapeutics’ biologically relevant, human-derived midbrain organoid models with molmir’s expertise on developing compounds and peptides to accelerate the development of therapeutics for Parkinson’s disease. By integrating high-fidelity in vitro models with advanced molecular sensing, the partnership seeks to enhance the predictive power of early-stage drug development.

OrganoTherapeutics is at the forefront of developing patient-specific 3D midbrain organoids, providing a physiologically relevant platform for drug screening and disease modeling. Their technology enables the study of neurodegenerative diseases in a human context, facilitating the identification of effective therapeutic candidates.

molmir, established in 2022 and based in Nara, Japan, specializes in capturing the movement of molecules at the atomic level. Their technologies, CHEmir and MAGmir, utilize analytical chemistry and solution nuclear magnetic resonance (NMR) to evaluate molecular kinetics. This approach aims to develop treatments for intractable diseases, including amyotrophic lateral sclerosis (ALS), by offering new possibilities for drug discovery.

The partnership will initially focus on a joint R&D project funded under a European innovation framework, with potential for future co-development initiatives.

For further information on molmir, visit: https://www.molmir.co.jp/en/

For inquiries to OrganoTherapeutics, visit: https://www.organo-therapeutics.com/contact